IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two April 16, 2024 Read More »
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock March 26, 2024 Read More »
6.7 Million Americans Live With Alzheimer’s – IGC Pharma Believes They Deserve Treatment Options Without Black Box Warnings May 8, 2024 Read More »
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation in Its Ongoing Phase 2 Clinical Trial April 25, 2024 Read More »